Minerva Neurosciences, Inc. (NERV)
2.42
+0.12
(+5.22%)
USD |
NASDAQ |
Nov 06, 16:00
2.415
0.00 (0.00%)
After-Hours: 20:00
Minerva Neurosciences Research and Development Expense (Annual) : 5.760M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 5.760M |
| December 31, 2024 | 11.90M |
| December 31, 2023 | 12.71M |
| December 31, 2022 | 14.65M |
| December 31, 2021 | 32.04M |
| December 31, 2020 | 22.04M |
| December 31, 2019 | 39.12M |
| December 31, 2018 | 34.89M |
| Date | Value |
|---|---|
| December 31, 2017 | 30.26M |
| December 31, 2016 | 20.44M |
| December 31, 2015 | 18.53M |
| December 31, 2014 | 42.91M |
| December 31, 2013 | 0.7085M |
| December 31, 2012 | 0.5504M |
| December 31, 2011 | 0.593M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Heron Therapeutics, Inc. | 12.43M |
| Tonix Pharmaceuticals Holding Corp. | 44.49M |
| Karyopharm Therapeutics, Inc. | 125.32M |
| Corbus Pharmaceuticals Holdings, Inc. | 70.10M |
| Ocugen, Inc. | 37.36M |